Solx said it added $2.1 million to its coffers in an options and debt round.
The Waltham, Mass.-based medical device company is seeking around $4.8 million in funding. The $2.1 million so far has come from 3 unnamed investors, according to a regulatory filing.
Solx raised $3.3 million earlier this year. The company is developing the Gold Shunt, a 24-karat gold micro-implant desigend to reduce the intra-ocular pressure caused by glaucoma "by using the natural pressure differential between the front and the back of the eye," according to its website.
The Gold Shunt device won clearance from Health Canada, according to Solx, which sold the exclusive rights for the device to I-MED Surgical north of the border in 2010.